Literature DB >> 29092098

Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Nancy D Perrier1, James D Brierley2, R Michael Tuttle3.   

Abstract

Answer questions and earn CME/CNE This is a review of the major changes in the American Joint Committee on Cancer staging manual, eighth edition, for differentiated and anaplastic thyroid carcinoma. All patients younger than 55 years have stage I disease unless they have distant metastases, in which case, their disease is stage II. In patients aged 55 years or older, the presence of distant metastases confers stage IVB, while cases without distant metastases are further categorized based on the presence/absence of gross extrathyroidal extension, tumor size, and lymph node status. Patients aged 55 years or older whose tumor measures 4 cm or smaller (T1-T2) and is confined to the thyroid (N0, NX) have stage I disease, and those whose tumor measures greater than 4 cm and is confined to the thyroid (T3a) have stage II disease regardless of lymph node status. Patients aged 55 years or older whose tumor is confined to the thyroid and measures 4 cm or smaller (T1-T2) with any lymph node metastases present (N1a or N1b) have stage II disease. In patients who demonstrate gross extrathyroidal extension, the disease is considered stage II if only the strap muscles are grossly invaded (T3b); stage III if there is gross invasion of the subcutaneous tissue, larynx, trachea, esophagus, or recurrent laryngeal nerve (T4a); or stage IVA if there is gross invasion of the prevertebral fascia or tumor encasing the carotid artery or internal jugular vein (T4b). The same T definitions will be used for both differentiated and anaplastic thyroid cancer, but the basic premise of the anatomic stage groups will remain the same. CA Cancer J Clin 2018;68:55-63.
© 2017 American Cancer Society. © 2017 American Cancer Society.

Entities:  

Keywords:  American Joint Committee on Cancer (AJCC); anaplastic; differentiated thyroid cancer; oncology; staging

Mesh:

Year:  2017        PMID: 29092098      PMCID: PMC5766386          DOI: 10.3322/caac.21439

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  27 in total

1.  Prognosis of patients with papillary thyroid carcinoma having clinically apparent metastasis to the lateral compartment.

Authors:  Yasuhiro Ito; Mitsuhiro Fukushima; Chisato Tomoda; Hiroyuki Inoue; Minoru Kihara; Takuya Higashiyama; Takashi Uruno; Yuuki Takamura; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka; Akira Miyauchi
Journal:  Endocr J       Date:  2009-06-09       Impact factor: 2.349

2.  An International Multi-Institutional Validation of Age 55 Years as a Cutoff for Risk Stratification in the AJCC/UICC Staging System for Well-Differentiated Thyroid Cancer.

Authors:  Iain J Nixon; Laura Y Wang; Jocelyn C Migliacci; Antoine Eskander; Michael J Campbell; Ahmad Aniss; Lilah Morris; Fernanda Vaisman; Rossana Corbo; Denise Momesso; Mario Vaisman; Andre Carvalho; Diana Learoyd; William D Leslie; Richard W Nason; Deborah Kuk; Volkert Wreesmann; Luc Morris; Frank L Palmer; Ian Ganly; Snehal G Patel; Bhuvanesh Singh; R Michael Tuttle; Ashok R Shaha; Mithat Gönen; K Alok Pathak; Wen T Shen; Mark Sywak; Luis Kowalski; Jeremy Freeman; Nancy Perrier; Jatin P Shah
Journal:  Thyroid       Date:  2016-02-25       Impact factor: 6.568

3.  Establishment of an intraoperative staging system (iStage) by improving UICC TNM classification system for papillary thyroid carcinoma.

Authors:  Yasuhiro Ito; Kiyoshi Ichihara; Hiroo Masuoka; Mitsuhiro Fukushima; Hiroyuki Inoue; Minoru Kihara; Chisato Tomoda; Takuya Higashiyama; Yuuki Takamura; Kaoru Kobayashi; Akihiro Miya; Akira Miyauchi
Journal:  World J Surg       Date:  2010-11       Impact factor: 3.352

4.  Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma.

Authors:  O Gimm; J Ukkat; H Dralle
Journal:  World J Surg       Date:  1998-06       Impact factor: 3.352

5.  The impact of age and gender on papillary thyroid cancer survival.

Authors:  J Jonklaas; G Nogueras-Gonzalez; M Munsell; D Litofsky; K B Ain; S T Bigos; J D Brierley; D S Cooper; B R Haugen; P W Ladenson; J Magner; J Robbins; D S Ross; M C Skarulis; D L Steward; H R Maxon; S I Sherman
Journal:  J Clin Endocrinol Metab       Date:  2012-04-10       Impact factor: 5.958

6.  Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis.

Authors:  Sophie Leboulleux; Carole Rubino; Eric Baudin; Bernard Caillou; Dana M Hartl; Jean-Michel Bidart; Jean-Paul Travagli; Martin Schlumberger
Journal:  J Clin Endocrinol Metab       Date:  2005-07-19       Impact factor: 5.958

7.  Extrathyroidal extension is not all equal: Implications of macroscopic versus microscopic extent in papillary thyroid carcinoma.

Authors:  Nimmi Arora; Harma K Turbendian; Theresa Scognamiglio; Patrick L Wagner; Stanley J Goldsmith; Rasa Zarnegar; Thomas J Fahey
Journal:  Surgery       Date:  2008-12       Impact factor: 3.982

Review 8.  Problems and controversies in the histopathology of thyroid carcinomas of follicular cell origin.

Authors:  Ronald Ghossein
Journal:  Arch Pathol Lab Med       Date:  2009-05       Impact factor: 5.534

9.  Optimal Cutoff Age for Predicting Mortality Associated with Differentiated Thyroid Cancer.

Authors:  Su-Jin Kim; Jun Pyo Myong; Hyunsuk Suh; Kyu Eun Lee; Yeo-Kyu Youn
Journal:  PLoS One       Date:  2015-06-23       Impact factor: 3.240

10.  Clinicopathological Significance of Minimal Extrathyroid Extension in Solitary Papillary Thyroid Carcinomas.

Authors:  Chang Gok Woo; Chang Ohk Sung; Yun Mi Choi; Won Gu Kim; Tae Yong Kim; Young Kee Shong; Won Bae Kim; Suck Joon Hong; Dong Eun Song
Journal:  Ann Surg Oncol       Date:  2015-06-16       Impact factor: 5.344

View more
  78 in total

1.  Clonal analysis of early-stage bilateral papillary thyroid cancer identifies field cancerization.

Authors:  Xingyun Su; Shitu Chen; Kuifeng He; Zhuochao Mao; Jiaying Ruan; Jie Zhou; Xiaodong Teng; Judy Jin; Thomas J Fahey; Weibin Wang; Lisong Teng
Journal:  Endocrine       Date:  2019-02-26       Impact factor: 3.633

2.  Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-up.

Authors:  R Michael Tuttle; Ali S Alzahrani
Journal:  J Clin Endocrinol Metab       Date:  2019-03-15       Impact factor: 5.958

3.  Establishment and validation of a nomogram model for predicting the survival probability of differentiated thyroid carcinoma patients: a comparison with the eighth edition AJCC cancer staging system.

Authors:  Ruyi Zhang; Mei Xu; Xiangxiang Liu; Miao Wang; Qiang Jia; Shen Wang; Xiangqian Zheng; Xianghui He; Chao Huang; Yaguang Fan; Heng Wu; Ke Xu; Dihua Li; Zhaowei Meng
Journal:  Endocrine       Date:  2021-04-06       Impact factor: 3.633

4.  Treatment outcomes of differentiated thyroid cancer with distant metastasis improve by tyrosine kinase inhibitors.

Authors:  Hiroyuki Iwasaki; Haruhiko Yamazaki; Hirotaka Takasaki; Nobuyasu Suganuma; Rika Sakai; Hirotaka Nakayama; Shinsuke Hatori; Soji Toda; Katsuhiko Masudo
Journal:  Oncol Lett       Date:  2019-03-21       Impact factor: 2.967

5.  Annexin A10 is a novel prognostic biomarker of papillary thyroid cancer.

Authors:  Xiaoyun Liu; Meijing Yang; Yang Guo; Xiaofei Lu
Journal:  Ir J Med Sci       Date:  2020-05-25       Impact factor: 1.568

6.  Assessment of the prognostic value and N1b changes of the eighth TNM/AJCC staging system for differentiated thyroid carcinoma.

Authors:  Jingtai Zhi; Yu Wu; Linfei Hu; Jingzhu Zhao; Hui Liu; Xianhui Ruan; Xiukun Hou; Jun Zhang; Xiangqian Zheng; Ming Gao
Journal:  Int J Clin Oncol       Date:  2019-08-14       Impact factor: 3.402

7.  Lenvatinib as a novel treatment for anaplastic thyroid cancer: A retrospective study.

Authors:  Hiroyuki Iwasaki; Haruhiko Yamazaki; Hirotaka Takasaki; Nobuyasu Suganuma; Hirotaka Nakayama; Soji Toda; Katsuhiko Masudo
Journal:  Oncol Lett       Date:  2018-10-05       Impact factor: 2.967

8.  Clinical outcomes and prognostic factors in patients with no less than three distant organ system metastases from differentiated thyroid carcinoma.

Authors:  Xin-Yun Zhang; Jian-Wen Sun; Zhong-Ling Qiu; Yang Wang; Xiao-Yue Chen; Jin-Hua Zhao; Quan-Yong Luo
Journal:  Endocrine       Date:  2019-07-17       Impact factor: 3.633

9.  The Updated AJCC/TNM Staging System for Papillary Thyroid Cancer (8th Edition): From the Perspective of Genomic Analysis.

Authors:  Kyubo Kim; Jin Hwan Kim; Il Seok Park; Young Soo Rho; Gee Hwan Kwon; Dong Jin Lee
Journal:  World J Surg       Date:  2018-11       Impact factor: 3.352

10.  Using the American Thyroid Association Risk-Stratification System to Refine and Individualize the American Joint Committee on Cancer Eighth Edition Disease-Specific Survival Estimates in Differentiated Thyroid Cancer.

Authors:  Sana A Ghaznavi; Ian Ganly; Ashok R Shaha; Crystal English; Jonathan Wills; R Michael Tuttle
Journal:  Thyroid       Date:  2018-08-02       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.